Assessment of attributable fraction is comparable between populations that have similar exposure (both qualitatively and quantitatively), so this assessment is less dependent on country-specific health care and insurance systems.
By contrast, the lay media likes to quote 'lifetime risk' (e.g., '1 in 3 of us will get cancer at some point in our lives'), but currently the calculation of this may not correspond to what one intuitively understands by the phrase; it is generally not comparable between populations, or over time.
This allows users to estimate, for example, interaction effects that are comparable between populations and construct high-order genotype-phenotype maps for further analyses of interactions (e.g., Álvarez-Castro and Rouzic 2008; Le Rouzic et al. 2008; Le Rouzic and Álvarez-Castro 2008).
As the size of the populations is variable and in order to have comparable results between populations, we select a sample of 77 individuals from each of these populations.
Likewise, baseline characteristics were comparable between the ITT population and subgroups analyzed (84-week completers [ Supplementary Table 1] and patients requiring a change in their treatment after 48 weeks [data not shown]).
The socioeconomic status of this group as assessed by the highest self-reported level of received education was comparable between the control population and the patients with RA (low: 27% versus 36%, middle: 37% versus 30%, and high: 36% versus 34%).
The mean age and body mass index were comparable between the two populations; however, there was a higher proportion of males in the Middle East population compared with Morocco (57.5% versus 37.5%, respectively).
First, in GS cell culture, Kit+ cells proliferated as actively as Kit− cells and frequency of SSCs was comparable between the two populations.
The mean daily dose of quetiapine XR was 562.50 ± 177.81 mg, which was comparable between the two populations.
